Breast Cancer Trial, Not Yet Recruiting NCT05131893 Sponsor: National Institute of Oncology, Hungary Condition: Breast Cancer
Back to Breast Cancer

Breast Cancer Trial, Not Yet Recruiting

NCT05131893
Not Yet Recruiting Not Applicable

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • Participants must be over 18 years of age.
  • The breast tumor must have been confirmed as invasive cancer through a core biopsy (a tissue sample taken with a needle).
  • The tumor must meet one of these size or stage conditions: shrinkage of the tumor is needed to make complete surgical removal possible; or shrinkage is needed to allow breast-conserving surgery; or, for tumors that are hormone receptor-positive and HER2-negative, the cancer is at stage IIB to IIIC; or, for tumors that are hormone receptor-negative, the cancer is at stage IIA to IIIC. (Note: people with locally advanced cancer that cannot currently be removed by surgery may also be considered if complete surgical removal later is a realistic goal — confirm with trial site.)
  • Participants must be in good general health, rated 0 or 1 on a standard medical scale called ECOG (meaning fully active or able to carry out light work).
  • Blood cell counts must meet minimum levels: white blood cells (neutrophils) at 1.5 G/l or above, platelets at 100 G/l or above, and haemoglobin at 10 g/dl or above.
  • Liver enzyme levels (ALT and AST) must be no more than 1.5 times the upper limit of the normal range.
  • Bilirubin (a substance processed by the liver) must be below 1.5 times the upper limit of the normal range, except for people with a condition called Gilbert's disease, where the limit is 3 times the upper limit.
  • Kidney function must be adequate, shown by creatinine levels below 1.5 times the upper limit of the normal range, or a kidney filtration rate (eGFR) above 60 ml/min.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People with confirmed or suspected cancer that has spread to distant parts of the body.
  • People who have not had the required tests to check for cancer spread — at minimum, a chest X-ray and abdominal ultrasound must have been done (CT scans of the chest, abdomen, and pelvis, plus a bone scan or PET/CT, are preferred where lymph nodes are involved).
  • People with known serious heart conditions, including significant abnormal heart rhythms, a heart attack or unstable chest pain within the past 6 months, untreated heart failure, long QT syndrome, or a heart failure rating of NYHA class II or above.
  • People with other serious ongoing physical or mental health conditions, or significant abnormal test results, that the treating doctor considers would make chemotherapy too risky.
  • People who are pregnant, or who are not willing to use a suitable non-hormonal method of contraception during the trial.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 7 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Gabor Rubovszky, NIO Hungary

Phone: +3612248600

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Not Applicable
Sponsor
National Institute of Oncology, Hungary
Registry
ClinicalTrials.gov
Start date
1 March 2022
Est. completion
1 March 2023

This date has passed while the registry still lists the trial as open to participants. Sponsors often update a trial's status without revising its projected end date, so it may well still be recruiting — but the record is out of date in at least one respect. Check with the study contact before relying on either.

Where this trial is recruiting

🇭🇺 Hungary

Primary endpoints

pathological complete remission rate

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 7 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov